Company profile
LadRx Corporation
OTC: LADX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 38
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ return on assets, Piotroski F
Methodology →Revenue TTM
$6.9k
Rev growth YoY (TTM)
-61.0%
Net income (FY)
-$1.6B
Employees
2
as of 2026-08-30
Market cap
$5.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$1.6B-$1.6B2024
Operating income-$3.6M-$3.6M2024
Total assets$839.5k$839.5k2024
Liabilities$2.3M$2.3M2024
Equity-$1.4M-$1.4M2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is LadRx Corporation’s revenue?
LadRx Corporation booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
FluoroPharma Medical, Inc.——PAO Group, Inc.——NovAccess Global Inc.——Arno Therapeutics, Inc.——Life Stem Genetics Inc.——Innovation1 Biotech Inc.——Neighbors
Los Angeles →Key facts
CEOJorge Kuri Slim
SectorHealthcare
IndustryBiotechnology
HeadquartersLos Angeles, CA
ExchangeOTC: LADX
Employees2
IPO date1989-03-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.